Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

tacurion.com

Stage

Series A | Dead

Total Raised

$15M

Last Raised

$15M

About Tacurion Pharma

Tacurion Pharma is a drug development firm lead by Drais Pharmaceuticals. Tacurion is developing ASP7035, a novel, small molecule, selective vasopressin 2 receptor agonist that will be evaluated in a Phase 2 clinical study for the treatment of nocturia. ASP7035 mimics the action of the natural agent, arginine vasopressin, and regulates renal water excretion.

Tacurion Pharma Headquarters Location

520 US Highway 22 Suite 201

Bridgewater, New Jersey, 08807,

United States

908-895-1200

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Tacurion Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Tacurion Pharma is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Tacurion Pharma Patents

Tacurion Pharma has filed 2 patents.

The 3 most popular patent topics include:

  • Amines
  • Muscarinic antagonists
  • Rare diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/16/2017

4/24/2018

Amines, Muscarinic antagonists, Rare diseases, Syndromes, Urology

Grant

Application Date

2/16/2017

Grant Date

4/24/2018

Title

Related Topics

Amines, Muscarinic antagonists, Rare diseases, Syndromes, Urology

Status

Grant

Latest Tacurion Pharma News

Tacurion Pharma Launches With $15M, Will Develop Drug Licensed From Astellas

May 8, 2013

VentureWire , (c) 2013 Dow Jones & Company, Inc. (c) 2013 Dow Jones & Company, Inc. Astellas Pharma Inc . are teaming up to launch a virtual company that will develop an Astellas drug. Astellas will license a drug called ASP7035 to Tacurion Pharma Inc., a virtual company that will be operated by the Drais team. The drug is a Phase IIa-ready, vasopressin V2 receptor selective agonist for nocturia.... Document DJFVW00020130507e957qq4sl

  • Where is Tacurion Pharma's headquarters?

    Tacurion Pharma's headquarters is located at 520 US Highway 22, Bridgewater.

  • What is Tacurion Pharma's latest funding round?

    Tacurion Pharma's latest funding round is Series A.

  • How much did Tacurion Pharma raise?

    Tacurion Pharma raised a total of $15M.

  • Who are the investors of Tacurion Pharma?

    Investors of Tacurion Pharma include InterWest Partners, Sutter Hill Ventures and Astellas Venture Management.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.